Morning neoadjuvant immunotherapy signals better survival in operable NSCLC
This retrospective dual-center analysis suggests chronomodulated scheduling of neoadjuvant checkpoint inhibitors may influence long-term survival in resectable NSCLC, a signal relevant to pharmacists building infusion schedules.
📅 Journal publication: 2026(online Aug 28, 2026)·Last updated: Oct 7, 2026
Infusion timing may enhance survival in NSCLC treatment.
Timing of neoadjuvant immunotherapy and chemotherapy may impact outcomes in operable non-small cell lung cancer (NSCLC) patients. Patients receiving infusions before 2 PM had better overall survival (89.1% vs. 68.3%) and a trend towards better disease-free survival. Timing of immunotherapy could be a crucial factor in treatment planning for NSCLC. Further research is needed to confirm these findings. Early immunotherapy infusion may improve survival in operable NSCLC.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Yu XY, Zhai WY, Xia ZZ, Ma K, Zhang BH, Yu X, Lin SC, Guo XT, Zhao ZR, Yu ZT
Citation:Yu XY, Zhai WY, Xia ZZ, et al. Impact of time-of-day and timing interval of neoadjuvant immunotherapy and chemotherapy infusions among patients with operable NSCLC using the inverse probability of treatment weighting method: a dual-center, retrospective study. Frontiers in immunology. 2026;17:1895311. doi:10.3389/fimmu.2026.1895311
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.